Article
Author(s):
Top news of the day from across the health care industry.
CVS Pharmacy has started selling cannabidiol (CBD)-based products at some at its stores in 8 states The Hill reported. According to the article, the products include topical CBD products, such as creams, sprays, and roll-ons, which will be marketed as an alternative source of pain relief. The products will be available in 800 stores in Alabama, California, Colorado, Illinois, Indiana, Kentucky, Maryland, and Tennessee, the article reported.
Officials with the FDA have decided not to approve the once-daily type 1 diabetes drug sotagliflozin (Sanofi SA and Lexicon Pharmaceuticals) as an add-on to insulin therapy, Reuters reported. According to the article, FDA panel members previously raised concerns about the risk of diabetic ketoacidosis associated with the drug. The companies had proposed a risk evaluation and mitigation strategy for the drug, as well as requiring regular testing of ketone levels, the article reported.
Recent CDC data show that flu prevalence continues to persist even after the peak of the season, The Wall Street Journal reported. According to the article, the CDC estimated that as of last week, 4.4% of physician visits were for flu-like symptoms, which is the highest figure for this time of the year since 1998. Flu prevalence is still widespread in 42 states, although it has decreased from 47 states and Puerto Rico for the week ending March 9, the article reported.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa